# NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct06941857/  
OnCo record `nct06941857` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cAPOX (capecitabine, oxaliplatin), fOLFIRI (5-FU, leucovorin, irinotecan), leucovorin (folinic acid), fluorouracil (5-FU) and other drugs in pancreatic cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.

## Summary

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT06941857 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 20 participants, started 2025-09-04 and due to reach its primary completion in 2028-12. Interventions recorded: Oxaliplatin; Irinotecan; Folinic Acid; 5-Fluorouracil (5-FU); NC410; Nivolumab; Ipilimumab. Conditions listed: Pancreatic Cancer. Primary outcome: Number of participants experiencing unexpected toxicities. Unexpected toxicities are toxicities related to the study drug required treatment discontinuation.. Pancreatic eligibility wording from the registry: "* Metastatic histologically or cytologically confirmed pancreatic ductal adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06941857
- Phase: 2
- Setting: A Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naïve, Metastatic Pancreatic Cancer
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06941857: https://clinicaltrials.gov/study/NCT06941857

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06941857.json